Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib + docetaxel versus docetaxel alone as second-line therapy for advanced non-small-cell lung cancer
ChiCTR1800016781Phase 4Recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Jul 2018
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Anlotinib + docetaxel treatment group with Docetaxel monotherapy group (2 arms). Primary endpoints: progression-free survival and disease control rate. Started Jul 2018; status: recruiting.
02
Drugs
anlotinibdocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR1800016781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800016781.